Measles and rubella eradication in the Americas
- PMID: 22185837
- DOI: 10.1016/j.vaccine.2011.04.059
Measles and rubella eradication in the Americas
Abstract
The challenge for regions embarking on measles elimination will be to maintain high population immunity with excellent vaccination coverage and high-quality surveillance. Meeting this challenge will be especially critical for dealing with importations of measles virus that will occur as long as the virus is circulating anywhere in the world. Implementation of measles elimination strategies will uncover the "hidden" disease burden of rubella and congenital rubella syndrome. As was the experience in countries of Latin America and the Caribbean (LAC), integrating the elimination of measles with the elimination of rubella will greatly enhance the capacity of countries to sustain progress in the reduction of measles mortality. Countries of LAC prioritized the routine national immunization program over short-term successes. While doing so, they have also encountered new opportunities to expand the benefits of disease control and elimination activities to other aspects of public health, most importantly towards improving health care for women and newborns and reducing inequities in health in the region's poorest communities. Implementation of similar strategies could lead to the global eradication of measles, rubella, and congenital rubella syndrome early this century, while strengthening routine immunization programs, and developing the capacity to introduce new and underutilized vaccines.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Combining Global Elimination Of Measles And Rubella With Strengthening Of Health Systems In Developing Countries.Health Aff (Millwood). 2016 Feb;35(2):327-33. doi: 10.1377/hlthaff.2015.1005. Health Aff (Millwood). 2016. PMID: 26858388
-
Global Measles and Rubella Laboratory Network, January 2004-June 2005.MMWR Morb Mortal Wkly Rep. 2005 Nov 4;54(43):1100-4. MMWR Morb Mortal Wkly Rep. 2005. PMID: 16267497
-
Measles elimination: progress, challenges and implications for rubella control.Expert Rev Vaccines. 2013 Aug;12(8):917-32. doi: 10.1586/14760584.2013.814847. Expert Rev Vaccines. 2013. PMID: 23984961 Review.
-
Measles and rubella elimination initiatives in the Americas: lessons learned and best practices.J Infect Dis. 2011 Jul;204 Suppl 1:S279-83. doi: 10.1093/infdis/jir216. J Infect Dis. 2011. PMID: 21666173
-
The principles and feasibility of disease eradication.Vaccine. 2011 Dec 30;29 Suppl 4:D70-3. doi: 10.1016/j.vaccine.2011.04.006. Epub 2011 Dec 19. Vaccine. 2011. PMID: 22188936 Review.
Cited by
-
Benefits and Challenges in Using Seroprevalence Data to Inform Models for Measles and Rubella Elimination.J Infect Dis. 2018 Jul 2;218(3):355-364. doi: 10.1093/infdis/jiy137. J Infect Dis. 2018. PMID: 29562334 Free PMC article.
-
Pathogenesis of viral infections during pregnancy.Clin Microbiol Rev. 2024 Jun 13;37(2):e0007323. doi: 10.1128/cmr.00073-23. Epub 2024 Feb 29. Clin Microbiol Rev. 2024. PMID: 38421182 Free PMC article. Review.
-
Results of the rubella elimination program in Catalonia (Spain), 2002-2011.Hum Vaccin Immunother. 2013 Mar;9(3):642-8. doi: 10.4161/hv.23260. Epub 2013 Jan 8. Hum Vaccin Immunother. 2013. PMID: 23299566 Free PMC article.
-
Rubella seroprevalence among pregnant women in Beijing, China.BMC Infect Dis. 2018 Mar 15;18(1):130. doi: 10.1186/s12879-018-3032-x. BMC Infect Dis. 2018. PMID: 29544450 Free PMC article.
-
Identification of Serologic Markers for School-Aged Children With Congenital Rubella Syndrome.J Infect Dis. 2015 Jul 1;212(1):57-66. doi: 10.1093/infdis/jiu604. Epub 2014 Oct 31. J Infect Dis. 2015. PMID: 25362195 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials